about
An unusual protein-protein interaction through coupled unfolding and bindingAnticalins: exploiting a non-Ig scaffold with hypervariable loops for the engineering of binding proteins.Neuropilin-1 stimulates tumor growth by increasing fibronectin fibril assembly in the tumor microenvironmentIdentification of accessible human cancer biomarkers using ex vivo chemical proteomic strategies.An earthworm protease cleaving serum fibronectin and decreasing HBeAg in HepG2.2.15 cells.Tenascin-W is a specific marker of glioma-associated blood vessels and stimulates angiogenesis in vitro.Peptide-targeted Nanoglobular Gd-DOTA monoamide conjugates for magnetic resonance cancer molecular imagingImpact of PINCH expression on survival in colorectal cancer patients.Co-purified gelatinases alter the stability and biological activities of human plasma fibronectin preparations.A novel synthetic naïve human antibody library allows the isolation of antibodies against a new epitope of oncofetal fibronectin.An effective targeted nanoglobular manganese(II) chelate conjugate for magnetic resonance molecular imaging of tumor extracellular matrixProteomic identification of plasma protein tyrosine phosphatase alpha and fibronectin associated with liver fluke, Opisthorchis viverrini, infection.Fibronectins in vascular morphogenesisSuppression of mitochondrial complex I influences cell metastatic properties.Innovative proteomics for the discovery of systemically accessible cancer biomarkers suitable for imaging and targeted therapiesMultiple cardiovascular defects caused by the absence of alternatively spliced segments of fibronectin.The effects of self-assembling peptide RADA16 hydrogel on malignant phenotype of human hepatocellular carcinoma cell.Design and characterization of a protein superagonist of IL-15 fused with IL-15Rα and a high-affinity T cell receptorBCAT1 expression associates with ovarian cancer progression: possible implications in altered disease metabolism.Targeting Syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenograftsCharacterisation and radioimmunotherapy of L19-SIP, an anti-angiogenic antibody against the extra domain B of fibronectin, in colorectal tumour models.Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure.Senescence-induced alterations of laminin chain expression modulate tumorigenicity of prostate cancer cells.Ovarian normal and tumor-associated fibroblasts retain in vivo stromal characteristics in a 3-D matrix-dependent mannerAnastellin, the angiostatic fibronectin peptide, is a selective inhibitor of lysophospholipid signaling.Early dysregulation of cell adhesion and extracellular matrix pathways in breast cancer progressionThe combined expression of the stromal markers fibronectin and SPARC improves the prediction of survival in diffuse large B-cell lymphoma.Differential secreted proteome approach in murine model for candidate biomarker discovery in colon cancer.TGF-β1 Induces Polypyrimidine Tract-Binding Protein to Alter Fibroblasts Proliferation and Fibronectin Deposition in Keloid.Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis.Fibronectin extra domain A (EDA) sustains CD133(+)/CD44(+) subpopulation of colorectal cancer cells.Imaging aspects of the tumor stroma with therapeutic implications.Stromal Modulators of TGF-β in Cancer.Jekyll and Hyde: the role of the microenvironment on the progression of cancer.Post-translational modifications of the extracellular matrix are key events in cancer progression: opportunities for biochemical marker development.Secretomic analysis of extracellular vesicles originating from Polyomavirus-negative and Polyomavirus-positive merkel cell carcinoma cell lines.The role of cytoskeleton and adhesion proteins in the resistance to photodynamic therapy. Possible therapeutic interventions.Integrin-mediated cell-matrix interaction in physiological and pathological blood vessel formation.Targeted Contrast Agent Specific to an Oncoprotein in Tumor Microenvironment with the Potential for Detection and Risk Stratification of Prostate Cancer with MRI.SERPINA5 inhibits tumor cell migration by modulating the fibronectin-integrin β1 signaling pathway in hepatocellular carcinoma.
P2860
Q27690840-46022671-3374-4A2C-BAE4-69ADE61C85E6Q30153481-3D4A4466-E847-4009-BD63-8C47BA6515E3Q30450729-7F97C54E-8D94-44EA-B6DA-01EF24550264Q33309341-5BB730BD-6BBE-4050-A837-4AFF1D58E8A8Q33386250-33290271-657C-4B23-88DC-2CF7EA47AAEFQ33694568-6F7C9557-2024-4BF7-842D-9382F3FEC4A5Q33782280-1A8224BF-C021-4AF3-A75E-004E36461290Q33852653-69777113-1619-48F9-A750-8D4B6A90BB35Q33857497-47D718A9-4B7A-4093-8B20-9F927355983AQ33870905-C7328334-2746-467C-88E6-B60C878F9C5CQ34036970-0590A198-1A08-486A-ACC4-7C5C282FD1D1Q34429098-AD6741B4-3F45-43F6-A5B1-27DDB61D1384Q34604585-AA7C0118-255A-45D7-B051-158A2936E322Q34695616-7C951B2A-23C9-4D8C-ACAB-67245B23C132Q34756337-170294F8-C9CD-410F-ACBA-659B8BC2A83FQ36148498-ABE00C13-9A11-4B5B-865F-7ACD424B2E9EQ36317361-A6AE8ABA-F436-49CA-9104-668A9D00BDBEQ36445933-D45B24E8-8B8C-48AB-B585-726FC54B60ACQ36544617-A96F8724-65A3-462F-ADA3-220763026EECQ36545764-EE95FB69-FE24-40EE-8A16-2A410C66CB5BQ36609642-D560E3E7-0E30-42EB-8A1F-5DF83A652A4AQ36672445-B43F93EB-8EF6-4C88-BDFB-74063DD0F66BQ36982102-83EC92C2-5C8E-48F3-AF78-3CFDFE981825Q37033701-9FF82972-94EC-4DBD-930B-7FE8F3D7A0DCQ37135504-1200D52E-3A94-41B6-AF0E-A73BB46873FCQ37316573-1AF5908E-2FFE-496C-BE82-FBDE27632B11Q37367971-11AD5BA6-D7CD-4E9C-941C-4785A6457FE6Q37441231-ECDCB5A0-3C0D-49F7-B7A2-9F3F2AEAC584Q37449229-80B1A6E6-0384-46A4-B685-C62716FF60D3Q37453905-3104F1A2-D0B6-4D5E-BAA4-273A72A870F1Q37566991-9CDD6EDB-9CF4-4C1F-9CD1-DAE6091F54C2Q37626064-D2B20F8D-E743-4531-BB83-EDD43615B163Q37628179-7DDA0648-80B2-422F-8342-892A01890368Q37815128-00DDD1E9-26A1-431A-85DD-1A2212256EB7Q37867110-785D5AA4-17A4-4B5A-8A2D-1B19B4A26FFEQ38390283-6B1013C2-3A8D-4D12-918D-BDE82A8522A1Q38400490-06DA820F-80FB-4587-916F-3ECFB7C462BCQ38501776-3CBFB48C-F3CA-4B21-B4B3-3A0C1416CB66Q38716380-595B2C4B-E221-4D14-99D4-8BA0AC635AD9Q39037593-B06923EA-6DB9-4602-8C72-93EDDF16BFD6
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Fibronectin as target for tumor therapy.
@ast
Fibronectin as target for tumor therapy.
@en
type
label
Fibronectin as target for tumor therapy.
@ast
Fibronectin as target for tumor therapy.
@en
prefLabel
Fibronectin as target for tumor therapy.
@ast
Fibronectin as target for tumor therapy.
@en
P2860
P356
P1476
Fibronectin as target for tumor therapy.
@en
P2093
Luciano Zardi
Manuela Kaspar
P2860
P304
P356
10.1002/IJC.21677
P50
P577
2006-03-01T00:00:00Z